Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both

Jazz Pharmaceuticals has delivered strong year-to-date performance, raising full-year revenue guidan

Bank of America Corp DE grew its position in Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) by 10.9% in the

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported second-quarter 2026 revenue of $1.21 billion, up 16% fr

Amundi raised its holdings in Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) by 2,445.3% in the first quart

Jazz Pharmaceuticals tops Q2 sales estimates and raises its 2026 revenue outlook despite an EPS miss

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) on Monday reported better-than-expected second-quarter sales

Jazz Pharmaceuticals plc (JAZZ) Q2 2026 Earnings Call Transcript

The headline numbers for Jazz (JAZZ) give insight into how the company performed in the quarter ende

Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $5.71 per share, missing the Zacks C

Jazz Pharmaceuticals NASDAQ: JAZZ reported second-quarter 2026 revenue of $1.21 billion, up 16% from

– Continued commercial execution drives record total revenues of $1.2 billion (+16% YoY) – – Company

For the second quarter of 2026, Aristotle Capital's Global Equity WM Composite posted a total return

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further t

Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in

Jazz Pharmaceuticals pairs its FDA-approved CBD blockbuster with a diversified drug portfolio, offer

President Donald Trump has announced that all generic drugs imported into the United States would co

Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combinatio

DUBLIN, July 20, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it wil

Wall Street analysts change ratings for FITB, TRVI, JAZZ, GPN, EAT, URBN, MNST. See full list on ben

Wall Street analysts change outlook on top stocks. For detailed ratings, upgrades/downgrades, see an

Canaccord Genuity analyst Gary Nachman initiates coverage on Jazz Pharmaceuticals (NASDAQ:JAZZ) w

Summary: Wall Street analysts changed rating for JAZZ, AFRM, MNDY, NGEN, FCEL, RRR, ABNB, KARO. See

Wells Fargo analyst Mohit Bansal maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight a

Barclays analyst Etzer Darout maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and

Deutsche Bank analyst Gregg Gilbert maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and r

Truist Securities analyst Gregory Renza maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy a

IWN delivered a 37.4% one-year return but carries higher fees, while ISCV offers a 0.06% expense rat

Jazz Pharmaceuticals teams with AbCellera on cancer therapies as analysts maintain positive targets

The collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in po

Top analysts changed outlook on top names. Check analyst ratings page for upgrades, downgrades, init

Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its

Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is estimated to report quarterly earni

Companies Reporting Before The Bell • Nomad Foods (NYSE:NOMD) is projected to report quarterly earn

    On Tuesday, 596 companies set new 52-week highs.

Stocks That Hit 52-Week Lows On Thursday

Stocks That Hit 52-Week Lows On Friday

Stocks That Hit 52-Week Highs On Friday